In the indirect pathway, anti-PD-1/PD-L1 or anti-CTLA-4 reinvigorates T cell immunity, which, in turn, shapes or phenotypically polarizes innate immune cell responses within the tumor microenvironment (TME). The gene discussed is CD274; the disease is neoplasm.